ADMP - Adamis Pharmaceuticals Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
Total Revenue
20,728
15,087
13,073
6,474
Cost of Revenue
14,320
9,798
7,420
4,854
Gross Profit
6,408
5,289
5,653
1,620
Operating Expenses
Research Development
16,162
18,794
7,527
9,697
Selling General and Administrative
26,898
25,948
22,819
17,128
Total Operating Expenses
43,060
44,742
30,346
26,825
Operating Income or Loss
-36,653
-39,453
-24,693
-25,204
Interest Expense
94
158
231
214
Total Other Income/Expenses Net
-
-11
-1,057
1,397
Income Before Tax
-36,803
-39,376
-25,878
-24,012
Income Tax Expense
-
-369
-339
-4,575
Income from Continuing Operations
-36,433
-39,007
-25,539
-19,437
Net Income
-36,433
-39,007
-25,539
-19,437
Net Income available to common shareholders
-36,433
-39,007
-25,539
-20,811
Reported EPS
Basic
-
-1.00
-0.90
-1.19
Diluted
-
-1.00
-0.90
-1.19
Weighted average shares outstanding
Basic
-
39,085
28,349
17,501
Diluted
-
39,085
28,349
17,501
EBITDA
-
-36,119
-22,584
-21,263